T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (884)	2/5/2002 2:24:24 PM
From: Icebrg	of 2243

>>Please feel free to add to the list>> In December 1999, Elan Corporation plc filed a new drug application (NDA) for ziconotide to receive FDA marketing approval. An approvable letter from the FDA was received by Elan in June 2000. Ziconotide is an w-conopeptide discovered in the University of Utah laboratory of Dr. Olivera. Ziconotide has been developed for the treatment of malignant and neuropathic pain, again employing the Medtronic SynchroMed® infusion system to facilitate intrathecal delivery. In 1998 Elan purchased Neurex Corporation for $740 million in order to acquire the rights to ziconotide. In January of 2000, Cognetix and Elan teamed up in a joint venture (JV) to develop and commercialize another Cognetix conopeptide, contulakin-G (CGX-1160). CGX-1160 is intended to be developed for the short-term management of post-operative pain.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next